Ammar Al-Chalabi

Jul 2, 2024 | nature.com | Alfredo Iacoangeli |Simon D. Topp |Puja R Mehta |Naomi Limbachiya |Kelly Williams |Wade K. Self | +15 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-022-34620-y, published online 12 November 2022The original version of this Article contained an error in Figure 4. Under the heading ‘Disease duration (months)’, all disease durations were reported as ‘disease duration’ rather than reporting the numerical value. The correct version now reports the disease duration in months instead of the original, incorrect ‘disease duration’.

Jun 13, 2024 | medrxiv.org | Oliver Pain |Ammar Al-Chalabi |Cathryn M. Lewis

OP provides consultancy services for UCB pharma. AAC reports consultancies or advisory boards for Amylyx, Apellis, Biogen, Brainstorm, Cytokinetics, GenieUs, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis, and Wave Pharmaceuticals. CML sits on the Myriad Neuroscience Scientific Advisory Board and is a Key Opinion Leader for UCB Pharma. OP is supported by a Sir Henry Wellcome Postdoctoral Fellowship [222811/Z/21/Z].